Vijaya G. Tirunagaru

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes”.

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-3555

N/A

0DataRank · unranked

81 citations

Anh T. Le, Andrea E. Doak, Vijaya G. Tirunagaru, Shevan Silva, Matthew R. Bull +6 more

Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.05.007

N/A

0DataRank · unranked

20 citations

Igor Odintsov, Vladimir Markov, Rebecca Caeser, Paweł Sobczuk, Sam E. Tischfield +14 more

Supplementary Figure S3 from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

(2023)10.1158/1078-0432.22478576

N/A

0DataRank · unranked

0 citations

Anh T. Le, Andrea E. Doak, Vijaya G. Tirunagaru, Shevan Silva, Matthew R. Bull +6 more

Data from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

(2023)10.1158/1078-0432.c.6529985

N/A

0DataRank · unranked

0 citations

Anh T. Le, Andrea E. Doak, Vijaya G. Tirunagaru, Shevan Silva, Matthew R. Bull +6 more

Data from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

(2023)10.1158/1078-0432.c.6529985.v1

N/A

0DataRank · unranked

0 citations

Anh T. Le, Andrea E. Doak, Vijaya G. Tirunagaru, Shevan Silva, Matthew R. Bull +6 more

Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial Results

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0762

N/A

0DataRank · unranked

11 citations

Thomas E. Stinchcombe, Mrinal M. Gounder, Gregory M. Coté, Glenn J. Hanna, Bradley Sumrall +16 more